Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Other Accumulated Expenses (2021 - 2025)

BioScience Health Innovations has reported Other Accumulated Expenses over the past 5 years, most recently at $228298.0 for Q3 2025.

  • Quarterly Other Accumulated Expenses rose 559.82% to $228298.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $228298.0 through Sep 2025, up 559.82% year-over-year, with the annual reading at $87074.0 for FY2023, 91.98% up from the prior year.
  • Other Accumulated Expenses was $228298.0 for Q3 2025 at BioScience Health Innovations, up from $47837.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $228298.0 in Q3 2025 and troughed at $404.0 in Q1 2022.
  • The 5-year median for Other Accumulated Expenses is $46777.5 (2025), against an average of $65806.8.
  • Year-over-year, Other Accumulated Expenses plummeted 86.68% in 2024 and then soared 559.82% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $625.0 in 2021, then plummeted by 35.36% to $404.0 in 2022, then surged by 21452.97% to $87074.0 in 2023, then plummeted by 60.26% to $34600.0 in 2024, then soared by 559.82% to $228298.0 in 2025.
  • Per Business Quant, the three most recent readings for BHIC's Other Accumulated Expenses are $228298.0 (Q3 2025), $47837.0 (Q2 2025), and $45718.0 (Q1 2025).